We found that combined inhibition of NF-κB and TNF/IL1 did not have an additive repressive effects on CFU in M0/1/2 subtypes of LCs, but synergized in M4/5 subtypes of LCs as well as LCs from AML patients secondary to MDS or therapy for other cancers (Figure 8C). This evidence concerns the gene NFKB1 and cancer.